jrnl9030

Publication Venue For

  • Epilepsy treatment patterns among patients with tuberous sclerosis complex.  391:104-108. 2018
  • Perceived embarrassment and caregiver burden in essential tremor caregivers.  383:205-210. 2017
  • Advancing stroke genomic research in the age of Trans-Omics big data science: Emerging priorities and opportunities.  382:18-28. 2017
  • Medical decision-making capacity and its cognitive predictors in progressive MS: Preliminary evidence.  380:38-43. 2017
  • Interleukin–6 (IL-6) rs1800796 and cyclin dependent kinase inhibitor (CDKN2A/CDKN2B) rs2383207 are associated with ischemic stroke in indigenous West African Men.  379:229-235. 2017
  • Caffeine, creatine, GRIN2A and Parkinson's disease progression.  375:355-359. 2017
  • Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric population.  375:371-375. 2017
  • Olfactory ability in normal pressure hydrocephalus as compared to Alzheimer's disease and healthy controls.  372:217-219. 2017
  • Physical activity, sedentary behavior, and aerobic capacity in persons with multiple sclerosis.  372:342-346. 2017
  • Daytime sleepiness and nighttime sleep quality across the full spectrum of cognitive presentations in essential tremor.  371:24-31. 2016
  • Brain activation changes during locomotion in middle-aged to older adults with multiple sclerosis.  370:277-283. 2016
  • Dissociation among hemodynamic measures in asymptomatic high grade carotid artery stenosis.  367:143-147. 2016
  • Evaluating the single seizure clinic model: Findings from a Canadian Center.  367:203-210. 2016
  • Neurogenomics in Africa: Perspectives, progress, possibilities and priorities.  366:213-223. 2016
  • Self-reported physical activity in essential tremor: Relationship with tremor, balance, and cognitive function.  366:240-245. 2016
  • Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial.  365:190-198. 2016
  • Gut microbiota composition and relapse risk in pediatric MS: A pilot study.  363:153-157. 2016
  • Relationship between symptom change, relapse activity and disability progression in multiple sclerosis.  362:121-126. 2016
  • Step-rate cut-points for physical activity intensity in patients with multiple sclerosis: The effect of disability status.  361:95-100. 2016
  • Itemized NIHSS subsets predict positive MRI strokes in patients with mild deficits.  358:221-225. 2015
  • Hemispheric differences in malignant middle cerebral artery stroke.  353:20-27. 2015
  • Accelerometer cut-points derived during over-ground walking in persons with mild, moderate, and severe multiple sclerosis.  340:50-57. 2014
  • Cognitive processing speed has minimal influence on the construct validity of Multiple Sclerosis Walking Scale-12 scores.  335:169-173. 2013
  • Gait and six-minute walk performance in persons with multiple sclerosis.  334:72-76. 2013
  • A brief olfactory test for Alzheimer's disease.  333:19-24. 2013
  • Psychometric properties of the Fatigue Severity Scale and the Modified Fatigue Impact Scale.  331:102-107. 2013
  • Physical fitness, walking performance, and gait in multiple sclerosis.  328:70-76. 2013
  • Creative innovation with temporal lobe epilepsy and lobectomy.  324:45-48. 2013
  • The dynamics of finger tremor in multiple sclerosis is affected by whole body position.  324:84-89. 2013
  • Premorbid physical activity predicts disability progression in relapsing-remitting multiple sclerosis.  323:123-127. 2012
  • Impaired cognitive function in patients with atherosclerotic carotid stenosis and correlation with ultrasound strain measurements.  322:20-24. 2012
  • Increasing age at disability milestones among MS patients in the MSBase Registry.  318:94-99. 2012
  • Postural control in multiple sclerosis: Effects of disability status and dual task.  315:44-48. 2012
  • Implementing clinical trials on an international platform: Challenges and perspectives.  313:1-6. 2012
  • Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortium.  307:22-29. 2011
  • Anxiety and depression severity are related to right but not left onset Parkinson's disease duration.  305:131-135. 2011
  • Post-streptococcal vasculopathy with evolution to Degos' disease.  300:157-159. 2011
  • GABAergic but not anti-cholinergic agents re-induce clinical deficits after stroke.  292:72-76. 2010
  • Turning off artistic ability: The influence of left DBS in art production.  281:116-121. 2009
  • Artistic creativity and DBS: A case report.  276:138-142. 2009
  • Creativity in Parkinson's disease as a function of right versus left hemibody onset.  276:179-183. 2009
  • Pooled analysis of patients with thunderclap headache evaluated by CT and LP: Is angiography necessary in patients with negative evaluations?.  276:123-125. 2009
  • Hemispatial neglect in cerebellar stroke.  275:133-138. 2008
  • Intravenous thrombolysis followed by intra-arterial thrombolysis and mechanical thrombectomy for the treatment of pediatric ischemic stroke.  275:151-153. 2008
  • Chronic inflammatory demyelinating polyradiculoneuropathy presenting as cauda equina syndrome in a diabetic.  260:267-270. 2007
  • CCR2-64I polymorphism and CCR5Δ32 deletion in patients with Alzheimer's disease.  225:79-83. 2004
  • Epstein-Barr virus nuclear antigen-1 (EBNA-1) associated oligoclonal bands in patients with multiple sclerosis.  173:32-39. 2000
  • Elevated cerebrospinal fluid and serum nitrate and nitrite levels in patients with central nervous system complications of HIV-1 infection: A correlation with blood-brain-barrier dysfunction.  156:53-58. 1998
  • Raised serum nitrate and nitrite levels in patients with multiple sclerosis.  145:77-81. 1997
  • Aids-associated vacuolar myelopathy and tumor necrosis factor-alpha (TNFα).  138:134-144. 1996
  • The electroencephalogram in neglect.  34:343-348. 1977
  • A memory defect in uremic encephalopathy.  26:245-249. 1975